5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

Published

Journal Article

With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer their patients. In this article, we outline current strategies for preventing prostate cancer in general, with a focus on the 5-α-reductase inhibitors (5-ARIs) finasteride and dutasteride. We discuss the two landmark randomized, controlled trials of finasteride and dutasteride, highlighting the controversies stemming from the results, and address the issue of 5-ARI use, including reasons why providers may be hesitant to use these agents for chemoprevention. We further discuss the recent US Food and Drug Administration ruling against the proposed new indication for dutasteride and the change to the labeling of finasteride, both of which were intended to permit physicians to use the drugs for chemoprevention. Finally, we discuss future directions for 5-ARI research.

Full Text

Cited Authors

  • Hamilton, RJ; Freedland, SJ

Published Date

  • January 2011

Published In

Volume / Issue

  • 9 /

Start / End Page

  • 105 -

PubMed ID

  • 21920036

Pubmed Central ID

  • 21920036

Electronic International Standard Serial Number (EISSN)

  • 1741-7015

International Standard Serial Number (ISSN)

  • 1741-7015

Digital Object Identifier (DOI)

  • 10.1186/1741-7015-9-105

Language

  • eng